Dimensional World EX US Core Equity 2 ETF(DFAX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Dimensional World EX US Core Equity 2 ETF
DFAX.US
News
View More

JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals

At the J.P. Morgan Healthcare Conference 2026, Novartis announced its strategy to enhance its neuroscience portfolio through mergers, acquisitions, and licensing deals. The $12bn acquisition of Avidity Biosciences is set to close in H1 2026, adding significant assets to its neuromuscular portfolio. Additionally, a licensing agreement with SciNeuro for an Alzheimer’s treatment was revealed, alongside a collaboration with Arrowhead for a Parkinson’s therapy. Novartis aims to strengthen its pipeline in neuromuscular and neurodegenerative diseases, positioning neuroscience as a key revenue driver.

Pharmaceutical Technology·
US
RNA
-0.12%
US
NVS
+0.83%
Pharmaceutical Technology·
US
RNA
-0.12%
US
NVS
+0.83%

SciNeuro and Novartis sign global licensing deal for Alzheimer’s antibody

SciNeuro Pharmaceuticals has entered a global licensing agreement with Novartis to develop an amyloid beta antibody for Alzheimer's disease. The collaboration will focus on early-stage development, with Novartis taking over later stages and commercialization. SciNeuro will receive $165 million upfront, potential research funding, and up to $1.5 billion in milestone payments. The deal is expected to close in the first half of 2026, pending regulatory approvals. Both companies aim to leverage their expertise to address the urgent need for new Alzheimer's therapies.

Pharmaceutical Technology·
US
NVS
+0.83%
Pharmaceutical Technology·
US
NVS
+0.83%

Key facts: Nestlé recalls infant formula over contamination risks; shares drop

Nestle is recalling infant formula from five brands due to contamination risks, potentially costing 1.2 billion Swiss francs. Shares fell by 0.3% after the announcement.1Nestlé is recalling certain infant formula products, including NAN and S-26, due to Bacillus cereus bacteria found in raw materials. No illnesses have been reported.2

TradingView·
US
NSRGY
-0.97%
US
NSRGF
-1.73%
TradingView·
US
NSRGY
-0.97%
US
NSRGF
-1.73%

Involving 46 countries! Nestlé announces a global large-scale recall of infant formula, potentially facing a sales loss of 1.2 billion Swiss francs

Nestlé has launched a large-scale recall in 46 countries due to the potential contamination of infant formula ingredients with harmful bacteria, involving multiple core brands. This move is expected to result in sales losses of up to CHF 1.2 billion and poses a serious impact on its brand reputation in the infant nutrition market and the execution capabilities of its new management team, highlighting the company's shortcomings in quality control and crisis response

Wallstreetcn·
US
NSRGY
-0.97%
US
NSRGF
-1.73%
Wallstreetcn·
US
NSRGY
-0.97%
US
NSRGF
-1.73%

Nestle infant formula recall widens to China, Brazil

Nestle's recall of infant nutrition products has expanded to China and Brazil, affecting at least 37 countries due to possible contamination with cereulide toxin. No illnesses have been reported yet. The recall, the largest in Nestle's history, has put pressure on the company and its new CEO, with shares down 4.5% this week. The recall includes products manufactured in Switzerland and Europe, and Nestle is testing ingredients and ramping up production to ensure supply.

Reuters·
US
NSRGF
-1.73%
US
NSRGY
-0.97%
Reuters·
US
NSRGF
-1.73%
US
NSRGY
-0.97%
© 2026 Longbridge｜Disclaimer